top of page
SCIG enduring module & webinar 

When & How: Subcutaneous Immunoglobulin (SCIg) Therapy

After participating in this multidisciplinary program, participants will be better able to;

  1. Recognize primary immunodeficiency with a focus on CVID;

  2. Identify secondary immunodeficiency in rheumatology; 

  3. Participate in collaborative management using immunoglobulin replacement;

  4. Consider the benefits of SCIg for patients, healthcare providers and institutions. 


Waserman v2.jpg

Susan Waserman, MSc, MDCM, FRCPC
Department of Medicine
McMaster University 
Hamilton, ON

Stephen Betschel, HBSc, MD
Associate Professor
Department of Medicine 
University of Toronto 
Toronto, ON

Juthaporn Cowan, MD, PhD
Assistant Professor 
Department of Medicine and Biochemistry, Microbiology, and Immunology
University of Ottawa

Ottawa, ON

This initiative has been sponsored in part by Takeda Pharmaceutical Company through an educational grant.

bottom of page